Introduction of exogenous wild‑type p53 mediates the regulation of oncoprotein 18/stathmin signaling via nuclear factor‑κB in non‑small cell lung cancer NCI‑H1299 cells

Chen,Sangyan; Zhao,Yan; Shen,Fang; Long,Dan; Yu,Ting; Lin,Xuechi

doi:10.3892/or.2019.6964

Introduction of exogenous wild‑type p53 mediates the regulation of oncoprotein 18/stathmin signaling via nuclear factor‑κB in non‑small cell lung cancer NCI‑H1299 cells

Authors:
- Sangyan Chen
- Yan Zhao
- Fang Shen
- Dan Long
- Ting Yu
- Xuechi Lin
View Affiliations

Affiliations: Department of Medical Laboratory, Changsha Medical University, Changsha, Hunan 410219, P.R. China
Published online on: January 10, 2019 https://doi.org/10.3892/or.2019.6964
Pages: 2051-2059

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Our previous studies demonstrated that high expression of oncoprotein 18 (Op18)/stathmin promotes malignant transformation of non‑small cell lung cancer NCI‑H1299 cells. Investigation of the cellular settings determined that NCI‑H1299 cells were genetically p53 deficient. In order to determine whether p53 deficiency is associated with Op18/stathmin‑mediated high levels of malignancy, exogenous wild‑type p53 (p53wt) was introduced into NCI‑H1299 cells in the present study to observe Op18/stathmin signaling changes and malignant behaviors. The results indicated that p53 downregulated Op18/stathmin expression and phosphorylation at the Ser25 and Ser63 sites in NCI‑H1299 cells, and the abilities of proliferation, colony formation and migration in multi‑dimensional spaces were simultaneously reduced. Introduction of p53wt inhibited the expression of the transcription factor nuclear factor‑κB (NF‑κB), and the activities of the Op18/stathmin upstream kinases cyclin‑dependent 2 (CDC2) and extracellular signal‑regulated kinase (ERK). Furthermore, blocking of NF‑κB signaling decreased CDC2 and ERK activation. Additionally, p53 intervention attenuated the secretion and protein expression of the immune inhibitory cytokine interleukin‑10, which was in accordance with the effect of NF‑κB signaling inhibition. Further experiments validated that p53 enhanced the sensitivity of NCI‑H1299 cells to Taxol through initiating the caspase‑3 and ‑9 intrinsic death pathways, and resulted in cell cycle arrest at the G1/S phases. These data indicated that exogenous p53wt mediates the regulation of Op18/stathmin signaling through the p53‑NF‑κB‑CDC2/ERK‑Op18/stathmin pathway, and that p53 deficiency is associated with high malignancy levels of NCI‑H1299 cells.

View Figures

View References

1	Lin X, Liao Y, Yang J, Su L, Zou H and Zuo Y: Regulation of the drug-resistance of carcinoma cells mediated by Op18/stathmin. Chem Life. 33:265–268. 2013.
2	Long D, Yu T, Chen X, Liao Y and Lin X: RNAi targeting STMN alleviates the resistance to taxol and collectively contributes to down regulate the malignancy of NSCLC cells in vitro and in vivo. Cell Biol Toxicol. 34:7–21. 2018. View Article : Google Scholar : PubMed/NCBI
3	Guntur VP, Waldrep JC, Guo JJ, Selting K and Dhand R: Increasing p53 protein sensitizes non-small cell lung cancer to paclitaxel and cisplatin in vitro. Anticancer Res. 30:3557–3564. 2010.PubMed/NCBI
4	Lv Y, Huo Y, Yu X, Liu R, Zhang S, Zheng X and Zhang X: TopBP1 contributes to the chemoresistance in non-small cell lung cancer through upregulation of p53. Drug Des Devel Ther. 10:3053–3064. 2016. View Article : Google Scholar : PubMed/NCBI
5	Riley T, Sontag E, Chen P and Levine A: Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol. 9:402–412. 2008. View Article : Google Scholar : PubMed/NCBI
6	Matt S and Hofmann TG: The DNA damage-induced cell death response: A roadmap to kill cancer cells. Cell Mol Life Sci. 73:2829–2850. 2016. View Article : Google Scholar : PubMed/NCBI
7	Zhang EB, Yin DD, Sun M, Kong R, Liu XH, You LH, Han L, Xia R, Wang KM, Yang JS, et al: P53-regulated long non-coding RNA TUG1 affects cell proliferation in human non-small cell lung cancer, partly through epigenetically regulating HOXB7 expression. Cell Death Dis. 5:e12432014. View Article : Google Scholar : PubMed/NCBI
8	Kracikova M, Akiri G, George A, Sachidanandam R and Aaronson SA: A threshold mechanism mediates p53 cell fate decision between growth arrest and apoptosis. Cell Death Differ. 20:576–588. 2013. View Article : Google Scholar : PubMed/NCBI
9	Lin X and Cao Y: Advances in the regulation of the signals on Op18/stathmin. Life Sci Res. 11:195–199. 2007.
10	Cassimeris L: The oncoprotein 18/stathmin family of microtubule destabilizers. Curr Opin Cell Biol. 14:18–24. 2002. View Article : Google Scholar : PubMed/NCBI
11	Belletti B and Baldassarre G: Stathmin: A protein with many tasks. New biomarker and potential target in cancer. Expert Opin Ther Targets. 15:1249–1266. 2011. View Article : Google Scholar : PubMed/NCBI
12	Johnsen JI, Aurelio ON, Kwaja Z, Jörgensen GE, Pellegata NS, Plattner R, Stanbridge EJ and Cajot JF: p53-mediated negative regulation of stathmin/Op18 expression is associated with G₂/M cell-cycle arrest. Int J Cancer. 88:685–691. 2000. View Article : Google Scholar : PubMed/NCBI
13	Bessho R, Matsubara K, Kubota M, Kuwakado K, Hirota H, Wakazono Y, Lin YW, Okuda A, Kawai M and Nishikomori R: Pyrrolidine dithiocarbamate, a potent inhibitor of nuclear factor kappa B (NF-kappa B) activation, prevents apoptosis in human promyelocytic leukemia HL-60 cells and thymocytes. Biochem Pharmacol. 48:1883–1889. 1994. View Article : Google Scholar : PubMed/NCBI
14	Shen F, Wu Y and Lin X: The pleiotropic function of P53. Basic Clin Med. 35:1672–1676. 2015.(In Chinese).
15	Olive KP, Tuveson DA, Ruhe ZC, Yin B, Willis NA, Bronson RT, Crowley D and Jacks T: Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell. 119:847–860. 2004. View Article : Google Scholar : PubMed/NCBI
16	Fuster JJ, Sanz-Gonzalez SM, Moll UM and Andres V: Classic and novel roles of p53: Prospects for anticancer therapy. Trends Mol Med. 13:192–199. 2007. View Article : Google Scholar : PubMed/NCBI
17	Wilking MJ, Singh C, Nihal M, Zhong W and Ahmad N: SIRT1 deacetylase is overexpressed in human melanoma and its small molecule inhibition imparts anti-proliferative response via p53 activation. Arch Biochem Biophys. 563:94–100. 2014. View Article : Google Scholar : PubMed/NCBI
18	Liu P, Kao TP and Huang H: CDK1 promotes cell proliferation and survival via phosphorylation and inhibition of FOXO1 transcription factor. Oncogene. 27:4733–4744. 2008. View Article : Google Scholar : PubMed/NCBI
19	Malumbres M and Barbacid M: Cell cycle, CDKs and cancer: A changing paradigm. Nat Rev Cancer. 9:153–166. 2009. View Article : Google Scholar : PubMed/NCBI
20	Perez de Castro I, de Carcer G and Malumbres M: A census of mitotic cancer genes: New insights into tumor cell biology and cancer therapy. Carcinogenesis. 28:899–912. 2007. View Article : Google Scholar : PubMed/NCBI
21	Dhillon AS, Hagan S, Rath O and Kolch W: MAP kinase signalling pathways in cancer. Oncogene. 26:3279–3290. 2007. View Article : Google Scholar : PubMed/NCBI
22	Wang J and Wu GS: Role of autophagy in cisplatin resistance in ovarian cancer cells. J Biol Chem. 289:17163–17173. 2014. View Article : Google Scholar : PubMed/NCBI
23	Lin X, Liu S, Luo X, Ma X, Guo L, Li L, Li Z, Tao Y and Cao Y: EBV-encoded LMP1 regulates Op18/stathmin signaling pathway by cdc2 mediation in nasopharyngeal carcinoma cells. Int J Cancer. 124:1020–1027. 2009. View Article : Google Scholar : PubMed/NCBI
24	Lin X, Tang M, Tao Y, Li L, Liu S, Guo L, Li Z, Ma X, Xu J and Cao Y: Epstein-Barr virus-encoded LMP1 triggers regulation of the ERK-mediated Op18/stathmin signaling pathway in association with cell cycle. Cancer Sci. 103:993–999. 2012. View Article : Google Scholar : PubMed/NCBI
25	Chen X, Liao Y, Long D, Yu T, Shen F and Lin X: The Cdc2/Cdk1 inhibitor, purvalanol A, enhances the cytotoxic effects of taxol through Op18/stathmin in non-small cell lung cancer cells in vitro. Int J Mol Med. 40:235–242. 2017. View Article : Google Scholar : PubMed/NCBI
26	Lin X, Liao Y, Chen X, Long D, Yu T and Shen F: Regulation of oncoprotein 18/stathmin signaling by ERK concerns the resistance to taxol in nonsmall cell lung cancer cells. Cancer Biother Radiopharm. 31:37–43. 2016. View Article : Google Scholar : PubMed/NCBI
27	Huan L, Bao C, Chen D, Li Y, Lian J, Ding J, Huang S, Liang L and He X: MicroRNA-127-5p targets the biliverdin reductase B/nuclear factor-κB pathway to suppress cell growth in hepatocellular carcinoma cells. Cancer Sci. 107:258–266. 2016. View Article : Google Scholar : PubMed/NCBI
28	Lu Y, Liu C, Cheng H, Xu Y, Jiang J, Xu J, Long J, Liu L and Yu X: Stathmin, interacting with Nf-κB, promotes tumor growth and predicts poor prognosis of pancreatic cancer. Curr Mol Med. 14:328–339. 2014. View Article : Google Scholar : PubMed/NCBI
29	Incrocci R, Barse L, Stone A, Vagvala S, Montesano M, Subramaniam V and Swanson-Mungerson M: Epstein-barr virus latent membrane protein 2A (LMP2A) enhances IL-10 production through the activation of Bruton's tyrosine kinase and STAT3. Virology. 500:96–112. 2017. View Article : Google Scholar : PubMed/NCBI
30	Kawaratani H, Moriya K, Namisaki T, Uejima M, Kitade M, Takeda K, Okura Y, Kaji K, Takaya H, Nishimura N, et al: Therapeutic strategies for alcoholic liver disease: Focusing on inflammation and fibrosis (Review). Int J Mol Med. 40:263–270. 2017. View Article : Google Scholar : PubMed/NCBI
31	Shan Y, He X, Song W, Han D, Niu J and Wang J: Role of IL-6 in the invasiveness and prognosis of glioma. Int J Clin Exp Med. 8:9114–9120. 2015.PubMed/NCBI
32	Zhang M, Gong W, Zhang Y, Yang Y, Zhou D, Weng M, Qin Y, Jiang A, Ma F and Quan Z: Expression of interleukin-6 is associated with epithelial-mesenchymal transition and survival rates in gallbladder cancer. Mol Med Rep. 11:3539–3546. 2015. View Article : Google Scholar : PubMed/NCBI
33	Olsen J, Kirkeby LT, Olsen J, Eiholm S, Jess P, Gögenur I and Troelsen JT: High interleukin-6 mRNA expression is a predictor of relapse in colon cancer. Anticancer Res. 35:2235–2240. 2015.PubMed/NCBI
34	Mittal SK and Roche PA: Suppression of antigen presentation by IL-10. Curr Opin Immunol. 34:22–27. 2015. View Article : Google Scholar : PubMed/NCBI
35	Klumpp D, Misovic M, Szteyn K, Shumilina E, Rudner J and Huber SM: Targeting TRPM2 channels impairs radiation-induced cell cycle arrest and fosters cell death of T cell leukemia cells in a Bcl-2-dependent manner. Oxid Med Cell Longev 2016. 80267022016.
36	Veena VK, Kennedy K, Lakshmi P, Krishna R and Sakthivel N: Anti-leukemic, anti-lung, and anti-breast cancer potential of the microbial polyketide 2,4-diacetylphloroglucinol (DAPG) and its interaction with the metastatic proteins than the antiapoptotic Bcl-2 proteins. Mol Cell Biochem. 414:47–56. 2016. View Article : Google Scholar : PubMed/NCBI
37	Oyaizu H, Adachi Y, Okumura T, Okigaki M, Oyaizu N, Taketani S, Ikebukuro K, Fukuhara S and Ikehara S: Proteasome inhibitor 1 enhances paclitaxel-induced apoptosis in human lung adenocarcinoma cell line. Oncol Rep. 8:825–829. 2001.PubMed/NCBI